Oncology & Cancer

Darolutamide slows spread of castration-resistant prostate cancer

(HealthDay)—Metastasis-free survival is significantly longer among men with nonmetastatic, castration-resistant prostate cancer treated with darolutamide versus placebo, according to a phase 3 study published online Feb. ...

Oncology & Cancer

Advancing therapy by measuring the 'games' cancer cells play

Despite rapid advances in targeted therapies for cancer, tumors commonly develop resistance to treatment. When resistance emerges, tumor cells continue to grow unchecked, despite all attempts to slow cancer progression. While ...

Oncology & Cancer

Fighting cancer one cell at a time

A team of scientists from Agency for Science, Technology and Research's (A*STAR) Genome Institute of Singapore (GIS) has identified a new approach to cancer therapeutics by targeting the evolution of cancer cells. This approach ...

page 29 from 40